Nottingham, UK. 20th August 2019 – MediConnect, the developer of a framework blockchain solution to trace and manage prescription medication, is pleased to announce the appointment of Gary Nelson, an IT development expert with over 25 years of experience in the IT sector and more recently in the blockchain industry, as Head of Engineering.
Nelson is currently a Senior Technical Architect at IBM, focusing on Enterprise Data Warehouse and Business Intelligence capabilities. Consulting across all business domains, he works on performance and optimisation improvements to existing hardware and software systems. Prior to that, he has headed Development IT teams for some of the largest companies in the world including Johnson and Johnson, Janssen Pharmaceuticals, Teradata, Avaya, Unisys, Barclays Bank, Tesco, Nokia, Kesco and Lloyds Banking Group.
As head of the engineering team at MediConnect, Nelson will lead the development of the MediConnect proof-of-concept platform, which is being designed to integrate seamlessly with partner pharmacies. He will work closely with Stratis, the enterprise blockchain technology company that is developing MediConnect’s bespoke blockchain solution. Stratis’ solutions are unique from other consultancies as they are based on Stratis’ own blockchain platform, built using C# on Microsoft’s .NET, the most popular enterprise programming language on the most widely-used enterprise framework.
MediConnect is a blockchain solution designed to track medication all the way through the supply chain from the point at which it is manufactured to its prescription by medical professionals and purchase by patients. It is being designed to comprise of two blockchains: a distributed ledger technology (DLT) solution to store confidential customer prescription data and provenance data for medicines, and a public blockchain that will handle the MEDI transactions relating to the purchase of medication embedded within the MediConnect platform.
Nelson says: “MediConnect’s platform and its use of blockchain technology will save lives so I am clearly delighted to join this exciting project. MediConnect has excellent technology partners in Stratis with some of the world’s top talent in the blockchain space. I am looking forward to working closely with them as we develop our proof-of-concept and MVP. Our ambitions are clear – we want to become the go-to platform to stop counterfeit and overprescribed medication from reaching patients worldwide and I am proud to be a part of this.”
Dexter Blackstock, CEO of MediConnect, adds: “We are extremely pleased that Gary has agreed to join the MediConnect team. He has a wealth of experience in the IT and blockchain industries which will be highly advantageous to the development of our blockchain solution. Gary will be working closely alongside Stratis as we build our blockchain solution to tackle the over-prescription of medication and provide traceability of drugs from manufacturers, wholesalers, prescribers and pharmacies all the way through to the patients.”
MEDI Token Sale
The MEDI Token Sale is now open and is due to conclude on 30th September 2019. To participate in the MEDI Token Sale, prospective purchasers are advised to visit: https://ico.mediconnect.io/
The total amount of MEDI tokens to be distributed is 500 million.
The target total funds to be raised is $10,000,000.
The nominal price of the MEDI token will be $0.20.
Bounty Programme
MediConnect launched the bounty programme for its MEDI Token Sale on 24th April 2019. The programme will reward users for promoting the MEDI Token Sale online by distributing up to 10,000,000 MEDI tokens in total (750 per person) between now and the conclusion of MediConnect’s Token Sale. For more information on how to participate, visit: https://gleam.io/kc18c/mediconnects-bounty-programme
Use of Proceeds
35% – Marketing
15% – Infrastructure
35% – Development
15% – Legal and accounting
Press release disclaimer: This is a paid press release. Coin Rivet recommends readers to undertake their own research on the company. Coin Rivet does not endorse and is not liable for any content or products on this page.
Disclaimer: The views and opinions expressed by the author should not be considered as financial advice. We do not give advice on financial products.